{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:33:59Z","timestamp":1791218039308,"version":"4.1.0"},"reference-count":202,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,3,19]],"date-time":"2008-03-19T00:00:00Z","timestamp":1205884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunological Reviews"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:p><jats:bold>Summary: <\/jats:bold> Ovarian cancer remains a challenging disease for which improved treatments are urgently needed. Most patients present with advanced disease that is highly responsive to surgery combined with platinum\u2010 and taxane\u2010based chemotherapy, with a state of minimal residual disease being achieved in many cases. However, chemotherapy\u2010resistant recurrent tumors typically appear within 1\u20135 years and are ultimately fatal. Recently, several groups have shown that ovarian tumors are often infiltrated by activated T cells at the time of diagnosis, and patients with dense infiltrates of CD3<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> T cells experience unexpectedly favorable progression\u2010free and overall survival. Other cell types in the immune infiltrate oppose anti\u2010tumor immunity, including CD4<jats:sup>+<\/jats:sup>CD25<jats:sup>+<\/jats:sup>FoxP3<jats:sup>+<\/jats:sup> regulatory T cells, CD8<jats:sup>+<\/jats:sup> regulatory T cells, macrophages, and dendritic cells. The composition of immune infiltrates is shaped by the expression of cytokines, chemokines, antigens, major histocompatibility complex molecules, and costimulatory molecules. The relationship between these various immunological factors is reviewed here with a strong emphasis on outcomes data so as to create a knowledge base that is well grounded in clinical reality. With improved understanding of the functional properties of natural CD8<jats:sup>+<\/jats:sup> T\u2010cell responses to ovarian cancer, there is great potential to improve clinical outcomes by amplifying host immunity.<\/jats:p>","DOI":"10.1111\/j.1600-065x.2008.00614.x","type":"journal-article","created":{"date-parts":[[2008,3,20]],"date-time":"2008-03-20T02:18:22Z","timestamp":1205979502000},"page":"101-116","source":"Crossref","is-referenced-by-count":144,"title":["The impact of T\u2010cell immunity on ovarian cancer outcomes"],"prefix":"10.1111","volume":"222","author":[{"given":"Brad H.","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,3,19]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pgp.0000130446.84670.93"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.1.61"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.18.1396"},{"key":"e_1_2_8_5_2","first-page":"212","article-title":"Standard treatment in advanced ovarian cancer in 2005","volume":"15","author":"Bookman MA.","year":"2005","journal-title":"the state of the art"},{"key":"e_1_2_8_6_2","first-page":"3194","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer","volume":"21","author":"Ozols RF","year":"2003","journal-title":"a Gynecologic oncology group study"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg036"},{"key":"e_1_2_8_8_2","first-page":"3","article-title":"Ovarian cancer","volume":"19","author":"Holschneider CH","year":"2000","journal-title":"epidemiology, biology, and prognostic factors"},{"key":"e_1_2_8_9_2","first-page":"47","article-title":"Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty","volume":"27","author":"Ozols RF.","year":"2000","journal-title":"Semin Oncol"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.39.6.585"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5"},{"key":"e_1_2_8_12_2","first-page":"S2","article-title":"Prognostic models in melanoma","volume":"24","author":"Halpern AC","year":"1997","journal-title":"Semin Oncol"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-003-0388-5"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)E0159-2"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19971021)74:5<492::AID-IJC3>3.0.CO;2-Z"},{"key":"e_1_2_8_16_2","first-page":"3491","article-title":"CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer","volume":"58","author":"Naito Y","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_8_17_2","first-page":"3932","article-title":"Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas","volume":"61","author":"Schumacher K","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_8_18_2","first-page":"5132","article-title":"Proliferative activity of intratumoral CD8(+) T\u2010lymphocytes as a prognostic factor in human renal cell carcinoma","volume":"61","author":"Nakano O","year":"2001","journal-title":"clinicopathologic demonstration of antitumor immunity"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1228"},{"key":"e_1_2_8_22_2","first-page":"235","article-title":"Serum vascular endothelial growth factor in epithelial ovarian neoplasms","volume":"74","author":"Chen CA","year":"1999","journal-title":"correlation with patient survival"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(97)00350-9"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi112"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.10.016"},{"key":"e_1_2_8_26_2","first-page":"4766","article-title":"Regulatory CD4(+)CD25(+) T cells in tumors from patients with early\u2010stage non\u2010small cell lung cancer and late\u2010stage ovarian cancer","volume":"61","author":"Woo EY","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1093"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1244"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509182102"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611533104"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2007.04.012"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm863"},{"key":"e_1_2_8_33_2","first-page":"739","article-title":"Contribution of the PD\u2010L1\/PD\u20101 pathway to T\u2010cell exhaustion","volume":"56","author":"Blank C","year":"2007","journal-title":"an update on implications for chronic infections and tumor evasion"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.02.029"},{"key":"e_1_2_8_35_2","first-page":"1457","article-title":"Cytokine\u2010induced killer cells","volume":"44","author":"Linn YC","year":"2003","journal-title":"NK-like T cells with cytotolytic specificity against leukemia"},{"key":"e_1_2_8_36_2","first-page":"421","article-title":"Correlation of NK T\u2010like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer","volume":"108","author":"Bamias A","year":"2008","journal-title":"association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2004.05.007"},{"key":"e_1_2_8_38_2","first-page":"1153","article-title":"Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer","volume":"13","author":"Kusuda T","year":"2005","journal-title":"Oncol Rep"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-003-0360-6"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.5.1861"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(91)90582-C"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.71"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910570305"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1997.4726"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.08.043"},{"key":"e_1_2_8_46_2","first-page":"226","article-title":"Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer","volume":"103","author":"Jiang YP","year":"2006","journal-title":"an independent prognostic factor for tumor progression"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2087"},{"key":"e_1_2_8_48_2","first-page":"458","article-title":"Class I histocompatibility antigen expression","volume":"38","author":"Moore DH","year":"1990","journal-title":"a prognostic factor for aneuploid ovarian cancers"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.02.004"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2005.01.019"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-003-0013-0"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.70.40"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.3.10.1142"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.06.006"},{"key":"e_1_2_8_55_2","first-page":"10","article-title":"SCP\u20101 cancer\/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer","volume":"4","author":"Tammela J","year":"2004","journal-title":"Cancer Immun"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1309\/15B66DQMFYYM78CJ"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1053\/hupa.2001.26455"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2007.05.012"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2000.6070"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1866"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050930"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10900"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2813"},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1446"},{"key":"e_1_2_8_65_2","first-page":"875","article-title":"Humoral p53 antibody response is a prognostic parameter in ovarian cancer","volume":"19","author":"Mayerhofer K","year":"1999","journal-title":"Anticancer Res"},{"key":"e_1_2_8_66_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0463.2002.11007805.x"},{"key":"e_1_2_8_67_2","doi-asserted-by":"crossref","unstructured":"GadducciA et al.Assessment of the prognostic relevance of serum anti\u2010p53 antibodies in epithelial ovarian cancer.1999;72:76\u201381.","DOI":"10.1006\/gyno.1998.5101"},{"key":"e_1_2_8_68_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-05-0035"},{"key":"e_1_2_8_69_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-0688"},{"key":"e_1_2_8_70_2","first-page":"4943","article-title":"CD46 expression is indicative of shorter revival\u2010free survival for ovarian cancer patients","volume":"26","author":"Surowiak P","year":"2006","journal-title":"Anticancer Res"},{"key":"e_1_2_8_71_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-4043"},{"key":"e_1_2_8_72_2","first-page":"474","article-title":"Lymphocyte subsets in patients with ovarian and breast cancer","volume":"18","author":"Schroder W","year":"1997","journal-title":"Eur J Gynaecol Oncol"},{"key":"e_1_2_8_73_2","first-page":"533","article-title":"Gains and losses of CD8, CD20 and CD56 expression in tumor stroma\u2010infiltrating lymphocytes compared with tumor\u2010associated lymphocytes from ascitic fluid and lymphocytes from tumor draining lymph nodes in serous papillary ovarian carcinoma patients","volume":"23","author":"Papadopoulos N","year":"2002","journal-title":"Eur J Gynaecol Oncol"},{"key":"e_1_2_8_74_2","doi-asserted-by":"publisher","DOI":"10.1159\/000058060"},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.1159\/000053824"},{"key":"e_1_2_8_76_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3083.2003.01288.x"},{"key":"e_1_2_8_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(02)00401-9"},{"key":"e_1_2_8_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.05.020"},{"key":"e_1_2_8_79_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1999.5430"},{"key":"e_1_2_8_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2005.05.001"},{"key":"e_1_2_8_81_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01741091"},{"key":"e_1_2_8_82_2","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.4049\/jimmunol.151.10.5472","article-title":"T cell receptor V beta 2 and V beta 6 mediate tumor\u2010specific cytotoxicity by tumor\u2010infiltrating lymphocytes in ovarian cancer","volume":"151","author":"Peoples GE","year":"1993","journal-title":"J Immunol"},{"key":"e_1_2_8_83_2","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.4049\/jimmunol.152.10.4993","article-title":"TCR V beta 3+ and V beta 6+ CTL recognize tumor\u2010associated antigens related to HER2\/neu expression in HLA\u2010A2+ ovarian cancers","volume":"152","author":"Peoples GE","year":"1994","journal-title":"J Immunol"},{"key":"e_1_2_8_84_2","first-page":"429","article-title":"Cytokine production by T\u2010cell lines derived from tumor\u2010infiltrating lymphocytes from patients with ovarian carcinoma","volume":"12","author":"Kooi S","year":"1993","journal-title":"tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells"},{"key":"e_1_2_8_85_2","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.1996.1055"},{"key":"e_1_2_8_86_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1998.00576.x"},{"key":"e_1_2_8_87_2","first-page":"263","article-title":"Tumor\u2010infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II\u2010restricted fashion","volume":"2","author":"Dadmarz RD","year":"1996","journal-title":"Cancer J Sci Am"},{"key":"e_1_2_8_88_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2000.01105.x"},{"key":"e_1_2_8_89_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1048-891x.2004.014175.x"},{"key":"e_1_2_8_90_2","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.4049\/jimmunol.146.5.1700","article-title":"Cytotoxic T cell clones isolated from ovarian tumor\u2010infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells","volume":"146","author":"Ioannides CG","year":"1991","journal-title":"J Immunol"},{"key":"e_1_2_8_91_2","first-page":"4257","article-title":"Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites","volume":"51","author":"Ioannides CG","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_8_92_2","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2001.114554"},{"key":"e_1_2_8_93_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19961104)68:3<276::AID-IJC2>3.0.CO;2-Z"},{"key":"e_1_2_8_94_2","first-page":"24","article-title":"T lymphocytes and cytokine production in ascitic fluid of ovarian malignancies","volume":"98","author":"Chen CK","year":"1999","journal-title":"J Formos Med Assoc"},{"key":"e_1_2_8_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(98)00070-3"},{"key":"e_1_2_8_96_2","first-page":"227","article-title":"T\u2010cell recognition of ovarian cancer","volume":"114","author":"Peoples GE","year":"1993","journal-title":"Surgery"},{"key":"e_1_2_8_97_2","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.4049\/jimmunol.151.10.5481","article-title":"HLA\u2010A2 presents shared tumor\u2010associated antigens derived from endogenous proteins in ovarian cancer","volume":"151","author":"Peoples GE","year":"1993","journal-title":"J Immunol"},{"key":"e_1_2_8_98_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-1247-5_8"},{"key":"e_1_2_8_99_2","first-page":"2420","article-title":"Overexpression of HER\u20102 in ovarian carcinomas","volume":"61","author":"Hellstrom I","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_8_100_2","first-page":"99","article-title":"Her\u20102\/neu expression in ovarian cancer","volume":"89","author":"Peethambaram PP","year":"2003","journal-title":"pre- and postexposure to platinum chemotherapy"},{"key":"e_1_2_8_101_2","first-page":"114","article-title":"T cell infiltration and MHC I and II expression in the presence of tumor antigens","volume":"94","author":"Nijman HW","year":"2001","journal-title":"an immunohistochemical study in patients with serous epithelial ovarian cancer"},{"key":"e_1_2_8_102_2","first-page":"e1138","article-title":"HER2 status in ovarian carcinomas","volume":"2","author":"Tuefferd M","year":"2007","journal-title":"a Multicenter Gineco study of 320 patients"},{"key":"e_1_2_8_103_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602259"},{"key":"e_1_2_8_104_2","first-page":"45","article-title":"Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER\u20102 peptides","volume":"17","author":"Fisk B","year":"1997","journal-title":"Anticancer Res"},{"key":"e_1_2_8_105_2","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200011)30:11<3338::AID-IMMU3338>3.0.CO;2-3"},{"key":"e_1_2_8_106_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006438507898"},{"key":"e_1_2_8_107_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10251"},{"key":"e_1_2_8_108_2","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.4049\/jimmunol.152.5.2393","article-title":"Association of HER2\/neu expression with sensitivity to tumor\u2010specific CTL in human ovarian cancer","volume":"152","author":"Yoshino I","year":"1994","journal-title":"J Immunol"},{"key":"e_1_2_8_109_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.2.432"},{"key":"e_1_2_8_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-7404(10)80030-1"},{"key":"e_1_2_8_111_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0029"},{"key":"e_1_2_8_112_2","first-page":"1289","article-title":"Generation of immunity to the HER\u20102\/neu oncogenic protein in patients with breast and ovarian cancer using a peptide based vaccine","volume":"5","author":"Disis M","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_113_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.06.171"},{"key":"e_1_2_8_114_2","first-page":"1014","article-title":"Immunization of cancer patients with a HER\u20102\/neu, HLA\u2010A2 peptide, p369\u2010377, results in short\u2010lived peptide\u2010specific immunity","volume":"8","author":"Knutson KL","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_115_2","first-page":"606","article-title":"P53\u2010specific T cell responses in patients with malignant and benign ovarian tumors","volume":"121","author":"Lambeck A","year":"2007","journal-title":"implications for p53 based immunotherapy"},{"key":"e_1_2_8_116_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050547"},{"key":"e_1_2_8_117_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02303486"},{"key":"e_1_2_8_118_2","first-page":"4214","article-title":"Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte\u2010recognized antigen system in epithelial cancers","volume":"5","author":"Peoples GE","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_119_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.9311"},{"key":"e_1_2_8_120_2","first-page":"12","article-title":"Th1\/Th2 CD4+ T cell responses against NY\u2010ESO\u20101 in HLA\u2010DPB1*0401\/0402 patients with epithelial ovarian cancer","volume":"4","author":"Qian F","year":"2004","journal-title":"Cancer Immun"},{"key":"e_1_2_8_121_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1902"},{"key":"e_1_2_8_122_2","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.4049\/jimmunol.153.9.4149","article-title":"Human tumor\u2010infiltrating CD4+ T cells react to B cell lines expressing heat shock protein 70","volume":"153","author":"Yoshino I","year":"1994","journal-title":"J Immunol"},{"key":"e_1_2_8_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(03)00253-9"},{"key":"e_1_2_8_124_2","first-page":"889","article-title":"Novel natural immunogenic peptides from Numb1 and Notch1 proteins for CD8+ cells in ovarian ascites","volume":"30","author":"Ishiyama S","year":"2007","journal-title":"Int J Oncol"},{"key":"e_1_2_8_125_2","first-page":"2509","article-title":"Shared immunoproteome for ovarian cancer diagnostics and immunotherapy","volume":"6","author":"Philip R","year":"2007","journal-title":"potential theranostic approach to cancer"},{"key":"e_1_2_8_126_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxg074"},{"key":"e_1_2_8_127_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2007.03323.x"},{"key":"e_1_2_8_128_2","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.1996.0301"},{"key":"e_1_2_8_129_2","doi-asserted-by":"publisher","DOI":"10.1593\/neo.07472"},{"key":"e_1_2_8_130_2","first-page":"1715","article-title":"Expression of IL\u201010 in patients with ovarian carcinoma","volume":"26","author":"Mustea A","year":"2006","journal-title":"Anticancer Res"},{"key":"e_1_2_8_131_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2001.00206.x"},{"key":"e_1_2_8_132_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.16.7708"},{"key":"e_1_2_8_133_2","first-page":"321","article-title":"Tumor\u2010host interaction","volume":"28","author":"Merogi AJ","year":"1997","journal-title":"analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas"},{"key":"e_1_2_8_134_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603918"},{"key":"e_1_2_8_135_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0537"},{"key":"e_1_2_8_136_2","first-page":"5573","article-title":"Epithelial ovarian cancer cells secrete functional Fas ligand","volume":"63","author":"Abrahams VM","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_8_137_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1518"},{"key":"e_1_2_8_138_2","first-page":"5113","article-title":"T\u2010cell apoptosis and suppression of T\u2010cell receptor\/CD3\u2010zeta by Fas ligand\u2010containing membrane vesicles shed from ovarian tumors","volume":"9","author":"Taylor DD","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_139_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1999.5448"},{"key":"e_1_2_8_140_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1998.5091"},{"key":"e_1_2_8_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64084-9"},{"key":"e_1_2_8_142_2","first-page":"5657","article-title":"Ovarian cancer\u2010induced immunosuppression","volume":"19","author":"Hassan MI","year":"1999","journal-title":"relationship to tumor necrosis factor-alpha (TNF-alpha) release from ovarian tissue"},{"key":"e_1_2_8_143_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.594"},{"key":"e_1_2_8_144_2","first-page":"2498","article-title":"Quantitative analysis of transforming growth factor beta 1 and 2 in ovarian carcinoma","volume":"5","author":"Gordinier ME","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_145_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2007.01.024"},{"key":"e_1_2_8_146_2","first-page":"1249","article-title":"Role of vascular endothelial growth factor in ovarian cancer","volume":"153","author":"Mesiano S","year":"1998","journal-title":"inhibition of ascites formation by immunoneutralization"},{"key":"e_1_2_8_147_2","first-page":"249","article-title":"Overexpression of Her\u20102\/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF\u2010kappa B","volume":"11","author":"Hsieh CY","year":"2004","journal-title":"implications for malignant ascites formation and tumor lymphangiogenesis"},{"key":"e_1_2_8_148_2","first-page":"793","article-title":"Tumor\u2010associated B7\u2010H1 promotes T\u2010cell apoptosis","volume":"8","author":"Dong H","year":"2002","journal-title":"a potential mechanism of immune evasion"},{"key":"e_1_2_8_149_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.9.4650"},{"key":"e_1_2_8_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.08.060"},{"key":"e_1_2_8_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2005.01.018"},{"key":"e_1_2_8_152_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1201-1339"},{"key":"e_1_2_8_153_2","doi-asserted-by":"publisher","DOI":"10.1038\/11383"},{"key":"e_1_2_8_154_2","first-page":"1731","article-title":"EBAG9\/RCAS1 in human breast carcinoma","volume":"85","author":"Suzuki T","year":"2001","journal-title":"a possible factor in endocrine-immune interactions"},{"key":"e_1_2_8_155_2","first-page":"623","article-title":"Clinical significance of RCAS1 as a biomarker of ovarian cancer","volume":"17","author":"Sonoda K","year":"2007","journal-title":"Oncol Rep"},{"key":"e_1_2_8_156_2","doi-asserted-by":"publisher","DOI":"10.1159\/000030003"},{"key":"e_1_2_8_157_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1997.4741"},{"key":"e_1_2_8_158_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1998.4974"},{"key":"e_1_2_8_159_2","first-page":"1723","article-title":"Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C\u2010C chemokines","volume":"150","author":"Negus RP","year":"1997","journal-title":"Am J Pathol"},{"key":"e_1_2_8_160_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1256"},{"key":"e_1_2_8_161_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.2.733"},{"key":"e_1_2_8_162_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2254"},{"key":"e_1_2_8_163_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-072587"},{"key":"e_1_2_8_164_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.8.5023"},{"key":"e_1_2_8_165_2","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.163.11.6251","article-title":"Identification of an IL\u201010\u2010producing HLA\u2010DR\u2010negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells","volume":"163","author":"Loercher AE","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_8_166_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02893460"},{"key":"e_1_2_8_167_2","first-page":"2385","article-title":"Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer","volume":"13","author":"Lambeck AJ","year":"2007","journal-title":"a potential role for interleukin 7"},{"key":"e_1_2_8_168_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2003.08.015"},{"key":"e_1_2_8_169_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2003.12.011"},{"key":"e_1_2_8_170_2","first-page":"619","article-title":"CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses","volume":"9","author":"Hakkarainen T","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_171_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.10.056"},{"key":"e_1_2_8_172_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2194"},{"key":"e_1_2_8_173_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/21.4.585"},{"key":"e_1_2_8_174_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1724"},{"key":"e_1_2_8_175_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1523"},{"key":"e_1_2_8_176_2","first-page":"7941","article-title":"Leveraging the immune system during chemotherapy","volume":"67","author":"Obeid M","year":"2007","journal-title":"moving calreticulin to the cell surface converts apoptotic death from \u201csilent\u201d to immunogenic"},{"key":"e_1_2_8_177_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2007.00573.x"},{"key":"e_1_2_8_178_2","first-page":"596","article-title":"High mobility group box I (HMGB1) release from tumor cells after treatment","volume":"30","author":"Dong Xda E","year":"2007","journal-title":"implications for development of targeted chemoimmunotherapy"},{"key":"e_1_2_8_179_2","first-page":"3689","article-title":"Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte\/macrophage\u2010colony stimulating factor\u2010secreting whole\u2010cell vaccines in HER\u20102\/neu tolerized mice","volume":"61","author":"Machiels JP","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_8_180_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.sj.6300124"},{"key":"e_1_2_8_181_2","first-page":"341","article-title":"Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model","volume":"13","author":"Bae SH","year":"2007","journal-title":"causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy"},{"key":"e_1_2_8_182_2","first-page":"1380","article-title":"Docetaxel\u2010induced lymphopenia in patients with solid tumors","volume":"89","author":"Kotsakis A","year":"2000","journal-title":"a prospective phenotypic analysis"},{"key":"e_1_2_8_183_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200010000-00007"},{"key":"e_1_2_8_184_2","first-page":"163","article-title":"The peripheral blood leukocyte phenotype in patients with breast cancer","volume":"23","author":"Melichar B","year":"2001","journal-title":"effect of doxorubicin\/paclitaxel combination chemotherapy"},{"key":"e_1_2_8_185_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10802"},{"key":"e_1_2_8_186_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600347"},{"key":"e_1_2_8_187_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1016-03"},{"key":"e_1_2_8_188_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002620000122"},{"key":"e_1_2_8_189_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2003.08.007"},{"key":"e_1_2_8_190_2","first-page":"3025","article-title":"Development of tumor\u2010infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy","volume":"7","author":"Demaria S","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_191_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0327"},{"key":"e_1_2_8_192_2","first-page":"S2\u2010105","article-title":"Mobilization of peripheral blood progenitor cells with paclitaxel\u2010based chemotherapy","volume":"24","author":"Shea TC.","year":"1997","journal-title":"Semin Oncol"},{"key":"e_1_2_8_193_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199902000-00011"},{"key":"e_1_2_8_194_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1994.1034"},{"key":"e_1_2_8_195_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0357"},{"key":"e_1_2_8_196_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3792"},{"key":"e_1_2_8_197_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1772"},{"key":"e_1_2_8_198_2","first-page":"1138","article-title":"Interferon\u2010gamma in the first\u2010line therapy of ovarian cancer","volume":"82","author":"Windbichler GH","year":"2000","journal-title":"a randomized phase III trial"},{"key":"e_1_2_8_199_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.0775"},{"key":"e_1_2_8_200_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0565"},{"key":"e_1_2_8_201_2","first-page":"1934","article-title":"Use of adoptive transfer of tumor\u2010infiltrating lymphocytes alone or in combination with cisplatin\u2010containing chemotherapy in patients with epithelial ovarian cancer","volume":"51","author":"Aoki Y","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_8_202_2","first-page":"501","article-title":"Prolonged disease\u2010free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor\u2010infiltrating lymphocytes","volume":"1","author":"Fujita K","year":"1995","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_203_2","first-page":"198","article-title":"Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor\u2010infiltrating lymphocytes and low\u2010dose recombinant interleukin\u20102","volume":"16","author":"Freedman RS","year":"1994","journal-title":"a pilot trial"}],"container-title":["Immunological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-065X.2008.00614.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-065X.2008.00614.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T16:05:23Z","timestamp":1694448323000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-065X.2008.00614.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,19]]},"references-count":202,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1600-065X.2008.00614.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-065x.2008.00614.x","archive":["Portico"],"relation":{},"ISSN":["0105-2896","1600-065X"],"issn-type":[{"value":"0105-2896","type":"print"},{"value":"1600-065X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,19]]}}}